MADRIGAL PHARMACEUTICALS, INC. 8-K

What Happened

• Madrigal Pharmaceuticals, Inc. (MDGL) filed an 8-K on June 17, 2026 reporting results of its June 17, 2026 Annual Meeting and board actions. Stockholders approved the Madrigal 2026 Stock Plan and the 2026 Employee Stock Purchase Plan (ESPP). At the meeting (record date April 23, 2026) 23,055,522 shares were outstanding and 21,322,829 shares were present or represented.
• On June 16, 2026 the Board adopted a Nonqualified Deferred Compensation Plan (effective August 1, 2026) for selected executives and non-employee directors. Also, effective July 1, 2026, Dr. Rebecca Taub will transition from employee to consultant under a consulting agreement paying $100,000 annually plus the same non-employee director compensation as other directors.

Key Details

• Voting results: 2026 Stock Plan — 19,118,851 for, 446,394 against, 25,739 abstain; 2026 ESPP — 19,546,766 for, 22,948 against, 21,270 abstain. PwC was ratified as auditor (21,256,315 for).
• Deferred Compensation Plan specifics: employees may defer up to 60% of base salary and up to 95% of annual cash performance bonus; non-employee directors may defer fees and equity; deferred amounts are always fully vested to participants.
• Company may make discretionary contributions subject to a vesting schedule but currently does not intend to contribute. Deferred amounts earn deemed returns based on participant election; payouts generally occur after separation (lump sum or installments up to 10 years).
• The plan is unfunded, will be maintained via a rabbi trust (assets are subject to company creditors), and is intended to comply with IRC Section 409A.

Why It Matters

• Approved equity plans (2026 Stock Plan and ESPP) provide tools for employee and director compensation and retention but can lead to future share dilution — investors should monitor disclosure of share reserves and future grant activity.
• The Deferred Compensation Plan gives senior staff and directors a way to defer pay (tax timing and retention benefit); however, obligations are unsecured and trust assets remain available to creditors, which is a creditor-risk consideration for investors.
• Dr. Taub’s consulting agreement signals continuity of scientific oversight for the company’s MASH programs while changing her employment status; the $100,000 fee plus director pay is a known, modest recurring expense.